TY - JOUR
T1 - Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals
T2 - Lessons from tramadol
AU - Epstein, David H.
AU - Preston, Kenzie L.
AU - Jasinski, Donald R.
N1 - Funding Information:
The authors thank John T. Sullivan, M.D., for his role in the human behavioral pharmacology studies of intravenous and oral tramadol. Dr. Epstein and Dr. Preston were supported by the Intramural Research Program of the NIH, National Institute on Drug Abuse.
PY - 2006/7
Y1 - 2006/7
N2 - Assessment of abuse potential of opioid analgesics has a long history in both laboratory animals and humans. This article reviews the methods used in animals and in humans and then presents the data collected in the evaluation of tramadol, an atypical centrally acting opioid analgesic approved for marketing in the United States in 1998. Finally, data on the abuse of tramadol from postmarketing surveillance and case reports are presented. The consistency between animal and human study results and the predictive value of both are discussed. Overall, there was substantial agreement between animal and human data, with each having predictive value. Nonetheless, it is suggested that abuse-potential screening of new medications would benefit from an organized, integrated cross-species program.
AB - Assessment of abuse potential of opioid analgesics has a long history in both laboratory animals and humans. This article reviews the methods used in animals and in humans and then presents the data collected in the evaluation of tramadol, an atypical centrally acting opioid analgesic approved for marketing in the United States in 1998. Finally, data on the abuse of tramadol from postmarketing surveillance and case reports are presented. The consistency between animal and human study results and the predictive value of both are discussed. Overall, there was substantial agreement between animal and human data, with each having predictive value. Nonetheless, it is suggested that abuse-potential screening of new medications would benefit from an organized, integrated cross-species program.
KW - Abuse-liability assessment
KW - Cross-species comparison
KW - Drug abuse/dependence
KW - Oxycodone
UR - http://www.scopus.com/inward/record.url?scp=33646530497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646530497&partnerID=8YFLogxK
U2 - 10.1016/j.biopsycho.2006.01.010
DO - 10.1016/j.biopsycho.2006.01.010
M3 - Article
C2 - 16497429
AN - SCOPUS:33646530497
SN - 0301-0511
VL - 73
SP - 90
EP - 99
JO - Biological Psychology
JF - Biological Psychology
IS - 1
ER -